



ACARIX PRESENTS ABSTRACT AT ACC.26 HIGHLIGHTING CADSCOR® SYSTEM'S DIAGNOSTIC UTILITY COMPARED TO STANDARD STRESS TESTS IN CHEST PAIN PATIENTS

Findings demonstrate high NPV, care time savings of up to 40 hours, and cost reductions exceeding \$100,000 per inpatient case, reinforcing the commercial and clinical case for global CADScor® adoption.

Malmö, Sweden – April 7, 2026 – Acarix AB (publ) (Nasdaq First North Premier Growth Market: ACARIX), a leader in acoustic-based cardiac diagnostics, announced the presentation of its abstract titled “A Novel Point-of-Care Device Comparing Diagnostic Utility to Standard Stress Tests in Chest Pain Patients” (26-A-8468-ACC). New data presented at the American College of Cardiology's 75th Annual Scientific Session & Expo (ACC.26) demonstrate that the CADScor® System delivers high diagnostic accuracy and substantial time and cost advantages over conventional stress testing in patients with chest pain.

Developed in collaboration with UC Davis, the abstract was presented by Dr. Surabhi Atreja and Dr. Pushkal Jadaun and reports findings from a U.S. study evaluating the CADScor® System in patients with chest pain. The data demonstrates a high negative predictive value (NPV) for the CADScor® System and indicates substantial operational benefits versus conventional stress testing pathways, including potential care time savings of up to 40 hours and cost reductions exceeding \$100,000 per inpatient case and \$4,000 per outpatient case.

“Presenting this data at ACC reinforces CADScor as an efficient, non-invasive point-of-care solution for chest pain assessment,” said Beji George, Head of Global Strategy and Therapy Development at Acarix. “In an environment of rising demand on healthcare systems, our technology offers clinicians a rapid tool that can help rule out significant coronary artery disease with high confidence. This has the potential to reduce unnecessary downstream testing, ease patient burden, and deliver meaningful time and cost efficiencies advancing our global strategy to expand adoption of innovative, accessible diagnostics.”

The CADScor® System holds both CE marking under EU MDR 2017/745 and FDA De Novo clearance as an acoustic diagnostic aid that delivers results in under 10 minutes at the point of care. Using highly sensitive acoustics and proprietary AI algorithms, it supports clinical decision-making by helping to rule out significant coronary artery disease (CAD) in symptomatic patients with at least 96% certainty which matches the gold standard in this field.



About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 60,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). The Company's Certified Adviser is Tapper Partners AB. For more information, please visit www.acarix.com

For more information, contact

Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments

[ACARIX PRESENTS ABSTRACT AT ACC.26 HIGHLIGHTING CADSCOR® SYSTEM'S DIAGNOSTIC UTILITY COMPARED TO STANDARD STRESS TESTS IN CHEST PAIN PATIENTS](#)